Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 779Lung Neoplasms 345Ovarian Neoplasms 323Breast Neoplasms 279Fallopian Tube Neoplasms 159Triple Negative Breast Neoplasms 145Small Cell Lung Carcinoma 144Neoplasms 137Squamous Cell Carcinoma of Head and Neck 123Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 85Head and Neck Neoplasms 80Endometrial Neoplasms 76Uterine Cervical Neoplasms 72Esophageal Neoplasms 71Adenocarcinoma of Lung 70Neuroblastoma 55Central Nervous System Neoplasms 53Lymphoma, Large B-Cell, Diffuse 49Carcinoma 49Recurrence 48Brain Neoplasms 48Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Stomach Neoplasms 31

Interventions

Cyclophosphamide 8Rituximab 7fludarabine 6dacetuzumab 6fludarabine phosphate 5blinatumomab 4Bortezomib 4ibrutinib 3Melphalan 3Lenalidomide 3Ifosfamide 3Etoposide 3Dexamethasone 3Bendamustine Hydrochloride 3AP 1903 reagent 3ponatinib 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Doxorubicin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunoproliferative Disorders × Carboplatin × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡